BeiGene (BGNE) Stock

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology firm planning to change its name to BeOne Medicines Ltd., has announced an investor webcast scheduled for December 16, 2024, at 8:30 am EST. During this event, the company's R&D leadership will share updates on BeiGene's innovative portfolio and pipeline, highlighting important presentations from the American Society of Hematology Meeting (ASH) and the San Antonio Breast Cancer Symposium.

The European Commission has recently approved BeiGene's TEVIMBRA, which is set to launch in the EU after its entry into the US market in October. The company's revenue per share has seen considerable growth, and both TEVIMBRA and BRUKINSA are expected to help BeiGene become profitable in the next 12 to 18 months. Analysts predict that BeiGene's revenues will hit $4.64 billion next year, making it a strong buy with a target price of $293 per share over the next year.

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company planning to change its name to BeOne Medicines, has announced that the European Commission has approved TEVIMBRA® (tislelizumab) to be used with chemotherapy for the initial treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. “Patients facing advanced gastric and esophageal cancers deal with significant challenges.

SAN MATEO, Calif.--(BUSINESS WIRE)-- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a worldwide oncology company planning to change its name to BeOne Medicines Ltd., has announced its participation in two upcoming investor conferences. The first is the Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET, followed by Citi's Global Healthcare Conference on Thursday, December 5 at 9:30 a.m. ET. Investors can watch the live webcasts of these events online.

SAN MATEO, Calif. & BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a worldwide cancer treatment company, has announced plans to change its name to BeOne Medicines Ltd. This change reflects its dedication to creating new treatments aimed at eradicating cancer by collaborating with the global community to help as many patients as possible. "Cancer is a major cause of death around the world and has a significant impact on individuals, families, and communities."

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a worldwide oncology firm, has shared its financial results and company updates for the third quarter of 2024. John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene, stated that the impressive results highlight the company's leadership in global oncology, which is supported by their unique research and development strengths and the successful launch of BRUKINSA. In the U.S., BRUKINSA is showing strong growth.

BeiGene, Ltd.'s TEVIMBRA is gaining attention in Europe for treating first-line gastro/gastroesophageal junction cancer and first-line esophageal squamous cell carcinoma. In the second quarter of 2024, BRUKINSA, a BTK inhibitor, achieved $637 million in sales, marking a 107% increase compared to the previous year, highlighting its market potential. The company's revenue for Q2 2024 reached $929 million, a 56% rise, but high research and development costs may require the use of financial tools within the next year.

SAN MATEO, Calif. and BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, has announced its participation in the Jefferies London Healthcare Conference on November 20, 2024, featuring a fireside chat at 2:30 p.m. GMT. You can watch the live webcast on the investors section of BeiGene's website at http://ir.beigene.com, https://hkexir.beigene.com/, or https://sseir.beigene.com/. A recorded version will also be available later.

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and the chair of the nominating and corporate governance committee. Co-founder, Chairman and CEO John V. Oyler issued the following statement: “We are saddened by the passing of our dear friend, Don Glazer. He helped guide the founding of the company in 2010 and was an ardent supporter.